Company intelligence / Profile preview
Intezyne Technologies
Tampa, Florida, United Statesintezyne.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Intezyne Technologies develops innovative cancer therapies using proprietary technologies aimed at increasing the effectiveness of existing treatments. Its lead program, IT‑139, has demonstrated synergy with checkpoint inhibitors such as pembrolizumab by reducing resistance to immunotherapy. The company reports compelling preclinical data and human safety data supporting further clinical development.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculePeptidesPolymer-drug conjugate therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships explicitly listed
Beyond the preview
Go deeper on Intezyne Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intezyne Technologies.